Seventy p atients with hepatosplenic schistosomiasis were treated with oxamniquine. The patients lived iti an endemic area and were evaluated 6, 18 and 24 months after treatment, during which time transmission in the area was interrupted. After treatment, clinicai improvement occurred in 49 (7 0 % ) o f the patients, as seen by reduction in visceromegaly and reversion o f liver nodules. Reversion o f hepatosplenic disease occurred in 28 (4 0 % ) patients and in liver nodularity in 26 (4 7 .3 % )patients after 24 months. Reversion o f hepatosplenic disease was seen in 12 (2 1 % ) patients and liver nodules disappeared in 4 (8.5% ) as early as 6 months after treatment. In general, hepatosplenomegaly reverses earlier than liver nodularity. I tis notable that reversion o f hepatosplenic disease occurred in many individuais with a history ofprevious treatment and also in some with advanced age. In fo u r cases this clinicai form o f the disease had existed fo r 20 years.
A fter 1922 mass treatm ent of schistosomiasis in Egypt gave the first indications that the prevalence of serious forms of the disease could be reduced as a consequence of specific therapy 1 9. The same observation was made by Sette 10 , after treating patients in Catende, Pernam buco (Brazil). Caio Benjamin D ias4, in addition to mentioning the benefits of treatm ent in the prevention of hepatosplenic forms of the disease, suggested the possibility of reversion of these forms " when not yet formed of irreversible lesions." Rodri gues da Silva 11 emphasized the benefits that could result from treatm ent in the prevention of severe forms of schistosomiasis. K loetzel7 dem onstrated that the number of eggs in feces diminished after treatment, in spite of reinfections and that treatment would prevent the occurrence of clinically severe forms. B in a2 confirmed th at treatm ent could prevent hepatosplenic disease. Bina and P ra ta 3 demonstrated the disappearance of hepatosplenic disease in some patients when this had lasted for less than six years.
The object of this study was to ascertain the effect of specific therapy on the reversion of hepa tosplenic schistosomiasis and to determine the rate at which reversion proceeds.
M A T E R IA L S A N D M E T H O D S
This study was conducted in Caatinga do Moura, Bahia, Brazil, an area hyperendemic for schistosomiasis, where a project for control of the disease was initiated in 1982. Seventy patients were classified as having hepatosplenic schistosomiasis accordingto the criteria of having the left lobe of the liver enlarged, usually prominent, hardened and/or nodular, and a spleen palpable in the absence of inspiration 13. Those patients which, after treatm ent, did not m eet at least one of these criteria were considered to have had a reversal of Patients were given a single oral dose of oxamniquine in capsule form using 15 mg/kg for adults and 20mg/kg for children of up to 30 kilograms body weight. The medicine was taken in our presence.
The patients were treated in January, 1983, and evaluated clinically, always by the same observer, before and 6, 18 and 24 months after treatment. Because they could not be found at the time of followup, 13 of the patients did not receive the second examination, 11 the third and 11 the fourth. Ali, however, received at least one clinicai examination after treatment. O ur index of clinicai improvement relative to condition at initial examination was a reduction greater than 2 cm of splenomegaly or of the left hepatic lobe and a reversion of the nodular liver. Progression in the opposite sense was considered as worsening of the condition.
After treatm ent two fecal examinations were made, at 6 and 18 months, to determine cure. The patients remained in the endemic area.
R E SU L T S
After treatm ent with oxamniquine, negative stool examinations were encountered at six months and at 18 months in 61 patients (87.2% ).
The possibility of-reinfection was small as a result of the use of molluscicide in the area (Bayluscide). This measure, in addition to drastically reducing the snail population, also reduced to zero the presence of infections in snails and in sentinel mice used to evaluate disease transm ission during the time of the study 5.
Six months after treatm ent, clinicai examination of 57 patients revealed that the size of the left lobe of the liver had diminished in 24(42.1% ) patients, remained unchanged in 28(49.1% ) and increased in 5(8.8% ). The m ean reduction in liver size was 3.0 cm. O f the patients evaluated at that time, 47(82.5% ) had nodular livers before treatment. O f these, 4(8.5% ) becam e smooth after six months. The size of the spleen remained unchanged in 24(42.1% ) patients, increased in 5(8.8% ) and reduced in 28(49.1 % ), with a mean reduction of 4.0 cm. Reversion of hepatosplenic schistosomiasis occurred in 12(21% ) patients during this period.
In the clinicai evaluation of 59 patients 18 months after treatm ent, the left hepatic lobe was reduced in 32(54.2% ) patients, remained unchanged in 20(34% ) and grew in 7( 11.8%). The mean reduction was 4.3 cm. O f the patients examined at this time, 48(81.4% ) had nodular livers before treatment. O f these, 11(22.9% ) becam e smooth to palpation. The size of the spleen remained unchanged in 18(30.5% ) of the patients, increased in 3(5% ) and was reduced in 38(64.4% ), with a mean reduction of 4.4 cm. Rever sion of hepatosplenic disease occurred in 23(39% ) patients.
The final clinicai examination of 59 patients 24 months after treatm ent dem onstrated that the left hepatic lobe diminished in 28(47.5% ) of patients, remained unchanged in 25(42.4% ) and increased in size in 6(10.2% ) patients. The mean reduction in size was 5.7 cm. O f the 59 patients examined, 48(81.3% ) had nodular livers at initial palpation. O f these, 25(52.1% ) became smooth. The size of the spleen remained unchanged in 25(42.4% ) of patients increased in 4(6.8% ) and was reduced in size in 30(50.8% ), with a mean reduction of 4.9 cm. Reversion of hepatosplenic disease occurred in 22(37.3% ) patients.
Cumulatively, we had reversion of hepatosplenic disease in 28(40% ) patients and of nodular livers in 26(47.3% ). Two patients were sent to govemment hospitais for splenectomy after examination at 18 months. O ne of these, (aged 61 years) was done because of hematemesis and the other, (15 years of age) because of anemia related to hypersplenism. Considering both hepatosplenomegaly and the liver surface in the 70 patients, it can be concluded that specific treatm ent o f schistosomiasis improved the condition of 49(70% ) patients. The condition of 6(8.6% ) patients worsened, and the condition of 15(21.4% ) was not changed.
In 45 patients that completed ali of the examinations, it was possible to study the rate of reversion. Reversion of hepatosplenic disease was found in 10 (22.2% ) patients after 6 months, in 6 (13.3% ) after 18 months and in 1 (4.2% ) after 24 months (Table 1 ). In the same periods, reversion of nodular liver occurred respectively in 2(5% ), 6(15% ) and 15(37.5% ) patients (Table 1 ). The regression of spleen occurs earlier than that of the liver nodules (Fig. 1). O f the 28 patients with reversion of hepatosplenic disease 13 were over 30 years old (T able 2). Their ages varied from 9 to 74 years with a mean of 32.5. Among them were 8(28.6% ) who gave a history of previous treatm ent 19(67.8% ) who had never been treated and 1(3.6% ) who could not remember. O f the 26 patients with a liver which was no longer nodular, 12(46.2% ) gave a history of specific treatment and 14(5 3.8% ) had no such history.
D IS C U S SIO N
The reversion of the hepatosplenic form of schistosomiasis can occur soon after specific treatment. In the present study we found that this had occurred in 21% of those treated within six months. Favourable results can occur later as indicated by our examinations after 18 and 24 months. The percentage of improved patients and of reversion in hepatosplenic disease after specific treatm ent is similar to that observed by Bina and P rata.3 The same occurred in relation to nodular livers. The nodules tended to disappear later than splenomegaly. W e believe that the interruption of transm ission by snail control did not influence our results since Bina and P rata3 obtained a similar percent of reversion of hepatosplenic disease than we did in a study in which transmission was not interrupted.
It is interesting to note that reversion of hepatosplenic disease also occurred in older indivi duais. In endemic areas the infection is initiated early in life, and hepatosplenic disease is often established before the age of 2 0.12 F our of our patients, already had hepatosplenic disease in 1964. EDB  06  12  7  8  6  6  ACM  EDB  EDB  EDB  07  13  9  6  IM P  5  DDB  IM P  08  13  8  8  7  ACM  ACM  DDB  IM P  IM P  09  14  9  8  6  6  ACM  ACM  EDB  EDB  10  19  11  8  IMP  EDB  6  DDB  IM P  DDB  11  22  9  7  ACM  EDB  12  24  10  9  8  5  EDB  EDB  13  29  11  7  8  11  ACM  DDB  IMP  EDB  14  29  6  7  8  9  6  5  EDB  DDB  15  36  6  3  EDB  ACM  3  IM P  EDB  EDB  16  37  10  12  11  11  ACM  EDB  EDB  EDB  17  42  4  10  8  6  4  REB  ACM  IM P  18  42  ACM  EDB  9  EDB  19  43  9  8  6  6  ACM  A CM  DDB  EDB  20  45  11  8  ACM  ACM  DDB  IM P  21  46  6  DDB  DDB  EDB  5  DDB  DDB  EDB  22  53  9  8  4  EDB  23  54  17  10  IM P  IM P  6  5  IM P  IM P  24  54  6  9  6  IM P  10  DDB  DDB  DDB  25  60  11  6  ACM  DDB  26  62  13  8  7  ACM  EDB  EDB  27  64  9  6  8  6  EDB  EDB  28  74  12  9  IM P  IM P  9 Thus, treatm ent is not only beneficiai to patients with recently established hepatosplenic disease, as was previously thought.3 Therefore, factors independent of the duration of the condition exist which regulate the reversibility of this clinicai form of schistosomiasis. It would be important to determine if there exists differences in the type of hepatic fibrosis inthose cases which do and do not regress following specific therapy.
The fact that many patients improved, including 8(28.6% ) patients with hepatosplenic disease who had previous treatm ent, shows that another treatm ent may be beneficiai. W e do not know if they had hepatosplenic disease at the time of their previous treatm ent and if such treatm ent failed to prevent or cure this clinicai form.
These observations indicate that it is inappropriate to attribute only to surgery the improvements seen in hepatosplenic patients presenting without hemorrhages in the digestive system who received both surgical treatment and specific therapy for schistosomiasis. It is evident that, at least among those schistosomiasis patients without a history of bleeding, specific therapy should be prescribed even in those with history of previous treatment. Patients should be followed for at least 18 months before surgical intervention is contemplated. Palavras Chaves: Esquistossomose. T ratam en to. Oxamniquine. Reversão da forma hepatosplênica.
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